[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rafael Holdings Inc (RFL)

Rafael Holdings Inc (RFL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 143,520
  • Shares Outstanding, K 52,000
  • Annual Sales, $ 920 K
  • Annual Income, $ -30,520 K
  • EBIT $ -36 M
  • EBITDA $ -33 M
  • 60-Month Beta 0.54
  • Price/Sales 153.68
  • Price/Cash Flow N/A
  • Price/Book 1.74

Options Overview Details

View History
  • Implied Volatility 208.52% (+64.96%)
  • Historical Volatility 94.78%
  • IV Percentile 53%
  • IV Rank 14.31%
  • IV High 1,250.29% on 08/13/25
  • IV Low 34.49% on 03/17/26
  • Expected Move (DTE 20) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 190
  • Volume Avg (30-Day) 721
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 4,597
  • Open Int (30-Day) 4,968
  • Expected Range 2.76 to 2.76

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.30 +112.31%
on 06/03/26
2.95 -6.44%
on 06/25/26
+1.44 (+109.09%)
since 05/26/26
3-Month
1.18 +133.90%
on 04/16/26
2.95 -6.44%
on 06/25/26
+1.50 (+119.05%)
since 03/26/26
52-Week
1.12 +146.43%
on 12/31/25
2.95 -6.44%
on 06/25/26
+1.08 (+64.29%)
since 06/26/25

Most Recent Stories

More News
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026. “Yesterday, we...

RFL : 2.76 (+1.85%)
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Topline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 ...

RFL : 2.76 (+1.85%)
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

NEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts...

RFL : 2.76 (+1.85%)
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026. “We remain...

RFL : 2.76 (+1.85%)
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. “We remain pleased...

RFL : 2.76 (+1.85%)
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for  Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation...

RFL : 2.76 (+1.85%)
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the...

RFL : 2.76 (+1.85%)
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

First data on treatment of NPC1 with Trappsol ® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients 1 showed...

RFL : 2.76 (+1.85%)
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation...

RFL : 2.76 (+1.85%)
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

RFL : 2.76 (+1.85%)

Business Summary

Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States.

See More

Key Turning Points

3rd Resistance Point 3.27
2nd Resistance Point 3.06
1st Resistance Point 2.91
Last Price 2.76
1st Support Level 2.55
2nd Support Level 2.34
3rd Support Level 2.19

See More

52-Week High 2.95
Last Price 2.76
Fibonacci 61.8% 2.25
Fibonacci 50% 2.04
Fibonacci 38.2% 1.82
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.